FPCM
AKBA icon

Financial Partners Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Financial Partners Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$15.9K Hold
27,486
– – ﹤0.01% 116
2022
Q3 		$8.69K Hold
27,486
– – ﹤0.01% 119
2022
Q2 		$9.71K Hold
27,486
– – ﹤0.01% 124
2022
Q1 		$19.7K Hold
27,486
– – ﹤0.01% 125
2021
Q4 		$62.1K Buy
+27,486
New +$74.9K 0.01% 125

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $715M AUM 19.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Financial Partners Capital Management's AKBA Position: Q4 2022 in Review

Financial Partners Capital Management held its Akebia Therapeutics (AKBA) position steady in Q4 2022 at 27,486 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #116.

Financial Partners Capital Management first reported a position in AKBA in Q4 2021 and has held it in 5 quarters since. The position peaked at $62.1K in Q4 2021. 75 funds tracked by Wall St. Rank hold AKBA as of Q4 2022.

  • Financial Partners Capital Management held 27,486 shares of Akebia Therapeutics worth $15.9K as of Q4 2022.
  • Financial Partners Capital Management left its Akebia Therapeutics share count unchanged in Q4 2022.
  • Akebia Therapeutics made up ﹤0.01% of Financial Partners Capital Management's portfolio in Q4 2022, its #116 holding.
  • Financial Partners Capital Management first reported a position in Akebia Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • Financial Partners Capital Management's Akebia Therapeutics position peaked at $62.1K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2022.

Based on Financial Partners Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.